AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03251612 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Based on sensitivity analysis
Description: * 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin
Study NCT04088864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is a purine antagonist antimetabolite
Study NCT04088864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a nitrogen mustard derivative alkylating agent
Study NCT04088864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CD22 CAR T
Description: Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
Study NCT04074343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Given PO
Study NCT04074343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT03790904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co.
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study NCT03790904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kin
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study NCT03790904 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: 15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study NCT02119949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
Study NCT02119949 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Description: The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
Study NCT03218566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indigo Aspiration System
Description: use of mechanical thrombectomy to treat pulmonary embolism
Study NCT03091582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive factors
Description: The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
Study NCT03091582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral factors
Description: The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
Study NCT03091582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase engagement of pleasant events
Description: Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
Study NCT01710800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Study NCT01710800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01550432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: 1,130 mg/day or 2,260 mg/day for 8 weeks
Study NCT01550432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 600 mg/day or 1,200 mg/day for 8 weeks
Study NCT01550432 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
Study NCT00144846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: albuterol sulfate inhalation aerosol
Study NCT00696553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored Nutrition Intervention
Description: Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
Study NCT00696553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition plus Exercise
Description: Nutrition plus Exercise
Study NCT02632812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide effervescent granules
Description: Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
Study NCT02632812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo effervescent granules
Description: Placebo effervescent granules (oral), twice daily for 7 days
Study NCT02632812 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen tablet
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days
Study NCT02632812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen tablet
Description: Naproxen tablet 550mg (tablet), twice daily for 7 days
Study NCT03416413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory phlebectomy
Description: Minor surgery to remove varicose vein tributaries
Study NCT03416413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy
Description: Injection of foam sclerosant into varicose vein tributaries
Study NCT03563313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM
Description: Participants will use the Tandem t:slim X2 with Control-IQ Technology \& Dexcom G6 CGM for 6 months at home.
Study NCT03563313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Description: Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
Study NCT02250534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Study NCT02488083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrashape
Description: circumference reduction
Study NCT04044703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin - model-based dosing regimen
Description: A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
Study NCT02305745 — intervention group
Intervention type: OTHER
Intervention: Observational
Study NCT03579238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CV4
Description: The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
Study NCT03579238 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: touching
Description: the clinician allows the participant's head to rest quietly upon his open palms on a table.
Study NCT03045809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urogenital infection point-of-care tests
Description: Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
Study NCT03699813 — intervention group
Intervention type: OTHER
Intervention: Comparison of two approaches to bleeding management
Study NCT02697734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osilodrostat
Description: In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg.
Study NCT02697734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: osilodrostat Placebo
Description: Matching Placebo in the form of filmcoated tablets for oral administration
Study NCT02030886 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sensimed Triggersfish® (TF)
Description: All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
Study NCT00588939 — intervention group
Intervention type: DEVICE
Intervention: Cell~vizio (Laser connfocal microscopy)
Description: completed during endoscopy
Study NCT02387424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-PD
Description: The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
Study NCT02387424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OAR
Description: Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
Study NCT00520052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: 5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
Study NCT02741115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Active drug
Study NCT02741115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT02686788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP001
Description: 600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
Study NCT01997970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Description: The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
Study NCT01997970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
Study NCT05254470 — intervention group
Intervention type: DEVICE
Intervention: Continuous Ultrasound
Description: 3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device
Study NCT04539756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive psychological intervention
Description: Participants will be asked to complete writing activities every other day. They will choose which activity they would like to complete each day, from a menu of six different activities. Each activity is a different positive psychology exercise.
Study NCT03817723 — intervention group
Intervention type: RADIATION
Intervention: c-arm cholangiography
Study NCT04539756 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Participants will be asked to complete the same writing activity each day, which will ask them to list their daily activities. Participants will be encouraged to process their daily activities superficially by the receiving the following instructions: (1) list each activity in brief, incomplete sentences, (2) document only facts about performing the activities, and (3) to not provide any information about emotional responses to performing the activities. By following these instructions, participants are presumably deriving less meaning from their activities, which may minimize gains in positive affect in the active control condition
Study NCT04272957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306
Description: HMPL-306 administered continuously as a single agent starting at 25 mg orally every day in a 28-day cycle and dose escalation is planned up to 200mg. Subjects may continue treatment with HMPL-306 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
Study NCT00621998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 0.5-6 mg/day
Study NCT00621998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 2.5-20 mg/day
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine- Fentanyl - Normal Saline
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine-Fentanyl-Normal Saline
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine- Fentanyl- Normal Saline
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Fentanyl
Description: Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + Fentanyl
Description: Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
Study NCT01558713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine + Fentanyl
Description: Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
Study NCT01158105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
Study NCT01554163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Description: Etoricoxib 30 mg tablet once daily for 12 weeks.
Study NCT01554163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 mg
Description: Celecoxib 200 mg once daily for 12 weeks
Study NCT03443258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Needs assesment tool integrated in nursing consultation.
Description: Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
Study NCT02572960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 2 weeks of Valsartan 80 mg per day
Study NCT02572960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Valsartan
Description: 2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
Study NCT02572960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 12 weeks of daily cholecalciferol treatment, 70 microgram per day
Study NCT02572960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 12 weeks of daily cholecalciferol treatment, 70 microgram per day
Study NCT02572960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cholecalciferol
Description: 12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
Study NCT02273765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + lamivudine + raltegravir
Description: In this arm, patients will receive the following medications :~* Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food
Study NCT02273765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir + lamivudine + efavirenz
Description: In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~* Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~* Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~* Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~* Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.
Study NCT03051373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel, S-1
Description: Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
Study NCT03051373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, cisplatin
Description: Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
Study NCT03867968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS Intervention
Description: Web-based training for family member.
Study NCT00673556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Intramuscular (IM)
Study NCT00673556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular (IM)
Study NCT04315116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate
Description: a single oral dose of pyrotinib maleate on day 1 \& day10 .
Study NCT04315116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg bid from day 7 to day 13
Study NCT01017263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lis-dexamphetamine
Description: Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
Study NCT00527150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
Study NCT00527150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
Study NCT00527150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
Study NCT00527150 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline Tartrate
Description: The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
Study NCT04158271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Position
Description: In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
Study NCT04158271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Description: In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube